SAB Biotherapeutics Inc. (SABS)

NASDAQ: SABS · IEX Real-Time Price · USD
0.982
-0.068 (-6.45%)
Dec 7, 2022 4:00 PM EST - Market closed
-6.45%
Market Cap 45.18M
Revenue (ttm) 32.80M
Net Income (ttm) -22.42M
Shares Out 43.03M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 45,330
Open 1.02
Previous Close 1.05
Day's Range 0.95 - 1.025
52-Week Range 0.621 - 10.23
Beta n/a
Analysts Buy
Price Target 5.51 (+460.9%)
Earnings Date Nov 21, 2022

About SABS

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-hum... [Read more]

Industry Biotechnology
Founded 2014
Employees 139
Stock Exchange NASDAQ
Ticker Symbol SABS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for SABS stock is "Buy." The 12-month stock price forecast is 5.51, which is an increase of 460.93% from the latest price.

Price Target
$5.51
(460.93% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

Study of SAB's fully-human polyclonal therapeutic to delay onset or progression of type 1 diabetes is the last step before investigational new drug (IND) filing Study of SAB's fully-human polyclonal the...

2 weeks ago - GlobeNewsWire

SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results

SIOUX FALLS, S.D., Nov. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically ...

3 weeks ago - GlobeNewsWire

SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases' at U.S. Pharma Partnering Summit 2022

Eddie Sullivan, Co-Founder, President and CEO, to present as SAB Biotherapeutics continues to execute on its partnering focused business strategy Eddie Sullivan, Co-Founder, President and CEO, to presen...

4 weeks ago - GlobeNewsWire

SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Ant...

SAB highlights data on SAB-176 for seasonal and pandemic influenza and SAB-185 for COVID-19, showing broad efficacy against highly mutating viruses associated with respiratory disease SAB highlights dat...

1 month ago - GlobeNewsWire

SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions

SIOUX FALLS, S.D. and GAITHERSBURG, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform tha...

1 month ago - GlobeNewsWire

SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-18...

SIOUX FALLS, S.D., Sept. 23, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifical...

2 months ago - GlobeNewsWire

SAB Biotherapeutics, Inc. (SABS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

SAB Biotherapeutics, Inc. (SABS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions ...

3 months ago - Zacks Investment Research

SAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results

Expects cash is sufficient to fund operations for the forward twelve months Expects cash is sufficient to fund operations for the forward twelve months

3 months ago - GlobeNewsWire

SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically ...

3 months ago - GlobeNewsWire

SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer

SIOUX FALLS, S.D., June 06, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically ...

6 months ago - GlobeNewsWire

SAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering...

In-person presentation titled ‘Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutics' to take place on June 7 in Park City, Utah

6 months ago - GlobeNewsWire

SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results

Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel platform

6 months ago - GlobeNewsWire

SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference

SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), announced today its participation at the H.C. Wainwright Global Investment Conference, which takes place May 23-26...

6 months ago - GlobeNewsWire

SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company's Board of Scientific Advisors

SIOUX FALLS, S.D., April 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically...

8 months ago - GlobeNewsWire

SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results

SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised patients

8 months ago - GlobeNewsWire

SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets

Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.

9 months ago - Zacks Investment Research

SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Du...

NIH is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study design statistically unworkable SAB-185 had advanced i...

9 months ago - GlobeNewsWire

SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively ...

In the FDA-conducted study, SAB-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of SARS-CoV-2 strains and variants through Delta

9 months ago - GlobeNewsWire

SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVI...

ACTIV-2 Phase 3 trial continuing as placebo-controlled study in Omicron variant COVID participants

9 months ago - GlobeNewsWire

SAB Biotherapeutics (SABS) Posts Data From COVID Treatment Study

Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.

10 months ago - Zacks Investment Research

On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Trial

SAB Biotherapeutics Inc (NASDAQ: SABS) has reported positive Phase 2 safety and efficacy data demonstrating that SAB-185 met the criteria required to move to Phase 3 in the National Institutes of Health...

10 months ago - Benzinga

SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phas...

SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September

10 months ago - GlobeNewsWire

SAB Biotherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference

SIOUX FALLS, S.D., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically ...

11 months ago - GlobeNewsWire

SAB Biotherapeutics Added to NASDAQ Biotechnology Index

SIOUX FALLS, S.D., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targete...

11 months ago - GlobeNewsWire

FDA Lab Testing Confirms SAB Biotherapeutics' COVID-19 Antibody Neutralizes Omicron Variant

SAB Biotherapeutics Inc (NASDAQ: SABS) announced that SAB-185, its COVID-19 therapeutic candidate, retains neutralization activity against the omicron variant in an in vitro pseudovirus model.  The resu...

11 months ago - Benzinga